Tag Archives: biotech stocks

Biostem U.S. Corp. HAIR

I’m on fire about Biostem U.S. Corp. (HAIR) today and the reason is in the ticker itself.

HAIR uses ethically harvested adult stem cells to super-charge balding scalps.

They say it’s virtually painless and you can do it on your lunch break.

You can imagine how much cash an outpatient cure for baldness would pull in!

And yet somehow HAIR is currently priced in the 20 cent range, so everyman traders like us still have a chance to see it on the ground floor.

See, HAIR is only now rolling its stem cell technique into hair transplant clinics in places like Orlando, Florida, where aging big shots want to stay young-looking forever.

HAIR will receive monthly revenue from each doctor who signs up.

Because they’re starting from near-zero here, every dollar moves the valuation needle.

And those first clinics just opened for stem cells a few weeks ago, so the inflection point here is as fresh as it gets!

Now that the wheels have finally started turning, HAIR could even become an attractive Big Biotech merger target.

After all, Propecia brings down $400 million a year for Merck.

And old Rogaine earned its maker $150 million a year back in the 90s.

The market is endless. Look for baldness cure online, 3 MILLION hits.

Just a few months ago, news that they’d found the cause of baldness drove the world wild.

A cure in five years? HAIR is already doing it!

HAIR is also turning heads as brokerage firms throw it cash for the privilege of getting their taste of this story before the Street catches on.

Elco Securities bought 20 million HAIR shares back in May at 25 cents apiece.

That’s a 65% premium over where HAIR was trading the day the deal was signed.

Remember, HAIR is now well under the $0.25 level so that position is still technically deep underwater.

Did the big boys at Elco get taken here or did they figure that $5 MILLION bet will be worth a lot more down the road?

All I know is that HAIR plans to use that cash to keep the lights on while its marketing team goes to work!

This board is stacked with top management from blue-chip corporations like Crocs.

Love or hate the shoes, Stephen Beck and Scott Crutchfield know how to build a multi-billion-dollar craze from the ground up, and they seem eager to do it again.

Bottom Line: HAIR just blasted out of the gate with a new revenue model and some of the biggest names in hair replacement on its team.

Smart players have gambled long green on this company and its technology.

Resources:
http://finance.yahoo.com/q?s=HAIR
http://www.google.com/finance?q=PINK%3AHAIR
http://ih.advfn.com/p.php?pid=squotesymbol=HAIR

Share This:

Penny Stocks NNVC, NanoViricides, Inc. UNSS, Universal Solar Technology Inc.

UNSS, Universal Solar Technology Inc. and NNVC, NanoViricides, Inc., NNVC.OB

NNVC is a development stage company that is creating special purpose nanomaterials for viral therapy. NNVC’s novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.

NNVC is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

Dengue is receiving significant international attention as it threatens over 40% of the world population, according to The World Health Organization (WHO).

Dengue cases with significant fatality rates have started rising in tropical countries this year already, as demonstrated by reports from India, Sri Lanka, Indonesia, Philippines, Cambodia, and Colombia, among others.

Dengue is endemic in Asia, Mexico, the Caribbean, Central America and many countries in South America. Dengue virus infections have occurred in the southern US states, including a current outbreak in Key West, and travel leads to sporadic cases of dengue in the US.

Dengue virus, a member of the Flaviviridae family of viruses that includes West Nile and Hepatitis C viruses, is transmitted to humans via female Aedes mosquitoes.

There are 4 different serotypes of Dengue virus that infect humans.

When a person is infected with Dengue virus for the first time, the disease may not be severe, inducing fever, muscle and joint pain, and rash. When the same person is later infected by a different Dengue virus serotype a more severe disease may develop; Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS) occurs in a significant portion of this population. This DHF/DSS may be due to ADE caused by antibodies produced during the first infection. According to the WHO, fatality rates of DHF/DSS can exceed 20%.

Currently there are no approved vaccines for prevention nor drugs for treatment of Dengue virus infection.

Check this out:

NNVC’s anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley (UC Berkeley).

Treatment with one of the anti-Dengue NNVC’s nanoviricides led to survival of 50% of the animals for the duration of study in the ADE model. In addition, animals treated with several anti-Dengue nanoviricides survived longer than the control animals treated with vehicle alone. This ADE model of infection is uniformly fatal in 100% of the infected animals within 5 days after infection.

Keep a close eye on NNVC from now on!

More about NNVC atwww.nanoviricides.com

**************************************************************

UNSS, Universal Solar Technology Inc., UNSS.OB

UNSS manufacturers solar products and provides solar power systems using advanced manufacturing technologies and equipments.

UNSS‘ products include solar-grade silicon material (ingots and wafers), solar modules, solar lights and solar power systems.

Arizona State University Photovoltaic Testing Laboratory has certified that UNSS Photovoltaic Modules satisfy the standards and requirements of the International Engineering Consortium and has passed the standards for selling products to countries in the European Union.

** UNSS reported the signing of a sales contract for $32,600,000 with CEZ Group, part of the largest electricity producer in the Czech Republic. The contract calls for the delivery of 20MW of monocrystaline solar modules to be delivered by the end of 2010.

The strategic goal of CEZ Group is to become the leader on the Central and Southeastern European electricity market. Apart from the production and sale of electricity, CEZ Group also deals in telecommunications, informatics, nuclear research, planning, construction and maintenance of energy facilities, mining raw materials, and processing energy by-products.

CEZ Group currently belongs among the three largest heat suppliers in the CzechRepublic.

Be sure UNSS is on your watch list!

UNSS could be at the beginning of a rally and you don’t want to be out of the action!

More about UNSS atwww.ustnevada.com/en

**************************************************************

NNVC and UNSS are on PennyOmega.com’s RADAR! Do your homework, and like always BE READY for the Action!!!

**************************************************************

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. awesomepennystocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold awesomepennystocks.com report  its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.

Share This: